TRPM2 and non-small cell lung carcinoma: Although osimertinib had a limited effect on decreasing c‐Myc mRNA levels (Figure 2B), it substantially decreased c‐Myc protein levels in EGFRm NSCLC cells and tumors largely via facilitating c‐Myc protein degradation as we previously reported.[18] However, c‐Myc knockdown in EGFRm NSCLC cells failed to result in TRPM2 reduction (Figure 2G), suggesting a nonessential role of c‐Myc in the regulation of TRPM2 expression at least in EGFRm NSCLC cells.